39 search results for: itch
EADV 2025 Congress
ADVENT at EADV 2025: Join Sanofi and Regeneron for three educational symposia on AD, CSU, and BP.
ADVENT On Air | Exploring PN as a Distinct and Unique Disease
Dr. Sonja Ständer and Dr. Shawn Kwatra discuss the unique features of prurigo nodularis (PN) as well as the characteristics that are shared with atopic dermatitis, and aim to raise awareness of PN among both physicians and patients.
Targeted Approaches to Holistic Management of PN
Professors Matthias Augustin and Sarina Elmariah evaluate how targeted therapies transform the management of prurigo nodularis, addressing the itch-scratch cycle and broader manifestations such as lesions.
Can advanced systemic therapies modify pathomechanisms in AD?
Dr. Ramien discusses evidence showing that advanced therapies can modify the mechanisms of atopic dermatitis, improving skin barrier function, normalizing the skin microbiome, and reducing chronic itch.
ADVENT On Air | Expert Discussions in Dermatology
Listen to the latest updates in type 2 inflammatory science and associated skin diseases, brought to you by leading dermatology experts in the field. ADVENT On Air podcasts feature scientific conversations that explore new research into the pathophysiology, clinical features, and disease burden for a range of dermatological diseases linked to type 2 inflammation, including atopic dermatitis (AD) and prurigo nodularis (PN). Hear new insights revealed through expert-led conversations below or in your preferred podcast app.
The Role of IL-4 and IL-13 in CSU Pathogenesis
Dive into the complex pathophysiology of chronic spontaneous urticaria (CSU), where mast cell degranulation drives the hallmark signs and symptoms. This interactive infographic elucidates how key type 2 cytokines, specifically IL-4 and IL-13, contribute to mast cell activation, immune cell trafficking into the skin, and neuronal sensitization in CSU, which ultimately leads to the release of mediators like histamine that cause wheals, angioedema, and itch.
The Patient Burden of Chronic Pruritus of Unknown Origin (CPUO)
An infographic describing the etiology, epidemiology, challenges in diagnosis and patient burden of CPUO.
World Congress of Dermatology (WCD) 2023 | Singapore
Highlights from the ADVENT symposium at the 2023 World Congress of Dermatology in Singapore.
Bullous Pemphigoid (BP): Exploring New Frontiers
Join experts Dédée Murrell, Donna Aline Culton, Joost Meijer and Enno Schmidt for an educational presentation on the clinical presentation, disease burden, diagnosis, and underlying pathophysiology of bullous pemphigoid (BP). Dive deeper into unmet needs and treatment challenges faced by these patients and how targeted therapies may address them.
Sarina Elmariah, MD, PhD, MPH
Associate Professor and Dermatology Director at the UCSF Centre for Itch and Neurosensory Disorders at the University of California in San Francisco, California, US
A brief overview of the pathophysiology of PN
Dr. Chovatiya explains that PN is primarily a chronic itch disease with a complex pathophysiology involving neuronal changes, type 2 inflammation, and fibrotic skin processes, affecting patients' overall well-being.
Describing Disease Control in PN
Dr. Chovatiya discusses PN, emphasizing that while itch is a major symptom, the disease's burden is multi-dimensional, affecting appearance, sleep, social life, and mental health, requiring comprehensive therapeutic solutions.
